In a phase II trial, 27 patients with resectable HCC were given either nivolumab or nivolumab/ipilimumab (CTLA-4 inhibitor) as neoadjuvant therapy and adjuvant therapy for two years [27]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.